Alvotech Shares Rise as FDA Accepts BLA for Entyvio Biosimilar
Alvotech's shares increased in premarket trading after the U.S. Food and Drug Administration accepted its Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Takeda’s Entyvio.
Topics: biosimilars drug approval